Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Expression data from FACS-sorted CD8+BTLA+ vs CD8+BTLA- Human Tumor-infiltrating Lymphocytes in Metastatic Melanoma


ABSTRACT: Adoptive T-cell Therapy (ACT) involves using tumor-infiltrating lymphocytes (TIL) isolated from metastatic melanoma and expanding them ex vivo prior to infusion into lympho-depleted patients. This is one of the most promising approaches to treat metastatic melanoma, with the rates of clinical response between 48-50% based on studies done at NCI, M.D. Anderson Cancer Center (Houston, TX), and Sheba Medical Center (Tel Aviv, Israel). In the Phase II ACT Trial at M.D. Anderson Cancer Center , our group has uncovered an association between positive clinical response and the amount of CD8+ tumor-infiltrating lymphocytes expressing B and T Lymphocyte Attenuator (BTLA), a reported inhibitory receptor on T-cells. We used microarrays to detail the differences in the global programme of gene expression between CD8+BTLA+ vs CD8+BTLA- TILs in order to understand the molecular basis of the clinical association. TILs were isolated by enzymatically digest the melanoma tumor fragments obtained from Stage IIIc/IV melanoma patients at M.D. Anderson Cancer Center. The TILs were expanded with high-dose IL-2 for two weeks prior to sorting by FACS (fluoresecence-activated cell sorter) for CD8+BTLA+ and CD8+BTLA- susbets. RNA was extracted from each sorted subsets and hybridized on Affymetrix microarrays

ORGANISM(S): Homo sapiens

SUBMITTER: Richard Wu 

PROVIDER: E-GEOD-43260 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2013-01-03 | GSE43260 | GEO
2013-12-31 | E-GEOD-42824 | biostudies-arrayexpress
2019-12-31 | E-MTAB-7278 | biostudies-arrayexpress
2013-12-31 | GSE42824 | GEO
2021-09-06 | E-MTAB-10116 | biostudies-arrayexpress
2015-05-05 | E-GEOD-65627 | biostudies-arrayexpress
2013-02-07 | E-GEOD-27928 | biostudies-arrayexpress
2020-05-01 | GSE145896 | GEO
2023-08-23 | GSE221590 | GEO
2020-07-01 | GSE153556 | GEO